Views

WHITE PAPER – Biotech and Breakthroughs in Immuno-Oncology

WHITE PAPER – Biotech and Breakthroughs in Immuno-Oncology

Key Points

  • Paradigm-shift in disease management with the approval of immuno-oncology agents, namely, checkpoint inhibitors, created a major shift in how patients with cancers are treated.
  • The significant clinical impact of checkpoint inhibitors led to what some have seen as a goldrush, others as a bubble, toward clinical development of immunotherapies.
  • Immuno-oncology agents have not by and large cured most patients in most cancers, hence new immunotherapeutic agents and combinations are needed.
  • Over the past 5 years, much of the BioPharma industry’s focus has been on expanding the range of immuno-oncology agents and combinations.

Complete the information below to download your free copy of the White Paper

For further information about our range of services

Contact Us

Share this

Related Articles

April 2021 Event Summary Available to Download
23 June 2021
April 2021 Event Summary Available to Download

Embedding patient journeys into clinical and commercial planning, for more focused decisions and improved patient outcomes.

Happy MedComms Day 2021
08 June 2021
Happy MedComms Day 2021

Happy MedComms Day 2021 from Cello Health’s Global Communications Team

EVENT – Cancer Progress, Virtual | May 4-6 2021
19 January 2021
EVENT – Cancer Progress, Virtual | May 4-6 2021

Join us at Cancer Progress, Virtual May 4-6 2021 ❝ Inspiring Cancer Progress through engaged stakeholder dialogue ❞

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us